Get the Stockscreener App
2.00
0.00%
+0.00
After Hours:
2.00
Regulus Therapeutics Inc stock is currently priced at $2.00, with a 24-hour trading volume of 263.32K.
It has seen a +0.00% increased in the last 24 hours and a -14.53% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.02 pivot point. If it approaches the $1.93 support level, significant changes may occur.
Previous Close:
$2.00
Open:
$2.05
24h Volume:
263.32K
Market Cap:
$130.93M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-1.1834
EPS:
-1.69
Net Cash Flow:
$-27.38M
1W Performance:
-9.50%
1M Performance:
-14.53%
6M Performance:
+38.89%
1Y Performance:
+22.70%
1D Range:
$1.95
$2.10
52W Range:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858 202 6300
Address
4224 Campus Point Court, Suite 210, San Diego, CA
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - Citizentribune
Citizentribune
Regulus Therapeutics Names New Chief Medical Officer - Contract Pharma
Contract Pharma
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PR Newswire
PR Newswire
Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity – Knox Daily - Knox Daily
Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update - MarketBeat
MarketBeat
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - Yahoo News UK
Yahoo News UK
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Regulus Therapeutics Inc (RGLS) Net Income 2024
RGLS net income (TTM) was -$30.04 million for the quarter ending December 31, 2023, a -6.05% decrease year-over-year.
Regulus Therapeutics Inc (RGLS) Cash Flow 2024
RGLS recorded a free cash flow (TTM) of -$27.38 million for the quarter ending December 31, 2023, a -5.77% decrease year-over-year.
Regulus Therapeutics Inc (RGLS) Earnings per Share 2024
RGLS earnings per share (TTM) was -$1.58 for the quarter ending December 31, 2023, a +15.05% growth year-over-year.
Regulus Therapeutics Inc Stock (RGLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CALSADA CRISPINA | Chief Financial Officer |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
5,782 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
10,056 |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):